On April 8, 2026, hormone health tracker Aavia published findings from one of the largest cycle-anchored datasets in women's health — over 250 million lived-experience data points collected from approximately 150,000 members who log health indicators an average of four times per week. Unlike traditional health datasets that treat the menstrual cycle as noise, Aavia's platform anchors every data point to cycle phase, enabling pattern detection that clinical research has historically missed.

Why It Matters

The pharmaceutical industry, AI model development, and clinical trial design have all been built on data that treats female biology as a constant — and Aavia's dataset directly challenges that paradigm. A platform that can flag PMDD 43x faster than the healthcare system demonstrates the power of cycle-anchored data at scale. For femtech investors, the dataset represents a moat: proprietary health data that improves with every user, creating network effects similar to what Fitbit achieved for activity tracking. The GLP-1 research gap is particularly timely given that Hims & Hers and other telehealth platforms are aggressively marketing weight-loss drugs to women without cycle-specific safety data. The CTA's recent CTA-2134 voluntary standards for women's health tech (published April 3) and this dataset release suggest that 2026 may be the year the industry finally takes sex-specific data seriously.

The headline finding is speed of diagnosis: Aavia's algorithms flag PMDD (premenstrual dysphoric disorder) in under 100 days from the start of logging, compared to the healthcare system's average of 12 years to diagnose the condition. The platform also identifies condition-specific "symptom fingerprints" — distinct patterns of symptom co-occurrence that differ meaningfully between PMDD, PCOS, PMS, and baseline populations, visible months before a clinical diagnosis would typically occur.

On birth control, Aavia tracked over 1,400 members for 12 months post-initiation and found a consistent month-one symptom spike that varies by contraceptive method. Copper IUD users experienced a 100% increase in menstrual cramps in month one before declining below baseline by month 12. The report also flags a significant research gap around GLP-1 drugs and menstrual cycles, noting a 7x increase in prescriptions among women with PCOS since 2021 despite the absence of clinical data on how these drugs interact with hormonal cycling.

Aavia's member base is 97% Gen Z and Gen Alpha women, and within three weeks of using the platform, members with anxiety and depression report a 52% decrease in stress and a 115% increase in confidence in their health. Founded in 2017 at MIT by Aagya Mathur, Aya Suzuki, and Alexis Wong, Aavia is positioning its dataset as foundational infrastructure for a field that has long lacked gender-specific data.

Sources

Update — 2026-04-09

Initial entry — story first created.